Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform
Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Feb 19, 2025
Trial Information
Current as of July 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different robotic surgery systems—HUGO RAS and Da Vinci—to see which one works better for treating prostate and kidney cancers. The study will include patients who are planning to undergo robot-assisted surgeries, like removing the prostate or part of the kidney. It’s designed to help doctors understand if one system is more effective or safer than the other.
To participate in the trial, patients must be at least 18 years old and meet specific health criteria. For prostate cancer patients, this means they should have a confirmed diagnosis, a life expectancy of more than 10 years, and be in a certain stage of the disease. For kidney cancer patients, they need to have a specific type of localized cancer confirmed by imaging tests like CT or MRI. Participants will be randomly assigned to one of the two robotic systems and will need to give their consent to join the study. This trial is important because it aims to improve surgical options for patients with these types of cancer, ultimately enhancing their treatment outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Prostate Cancer (Group A)
- • Age ≥ 18 years.
- • Life expectancy greater than 10 years.
- • Diagnosis of prostate cancer following prostate needle biopsy.
- • Clinical stage cT1-T3b, N0-1 disease.
- • Positive anesthetic fitness assessment for robot-assisted radical prostatectomy.
- • Provision of informed consent for the study.
- • Patients with Kidney Cancer (Group B)
- • Age ≥ 18 years.
- • Radiological diagnosis of organ-confined kidney cancer at clinical stage T1a or T1b.
- • Underwent CT and/or MRI of the abdomen with contrast medium.
- • Positive anesthetic fitness assessment for robot-assisted partial nephrectomy.
- • Provision of informed consent for the study.
- Exclusion Criteria:
- • Patients with Prostate Cancer (Group A)
- • Expression of a preference for radical treatment other than surgery (e.g., external radiotherapy).
- • Metastatic prostate cancer (M1).
- • Other conditions deemed by healthcare professionals to contraindicate inclusion in the study.
- • Patients with Kidney Cancer (Group B)
- • Indication for radical nephrectomy.
- • Metastatic kidney cancer (M1).
- • Other conditions deemed by healthcare professionals to contraindicate inclusion in the study.
About Irccs Azienda Ospedaliero Universitaria Di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna is a prestigious research and healthcare institution in Italy, renowned for its commitment to advancing medical science and patient care through innovative clinical research. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, facilitating the translation of laboratory findings into effective treatment strategies. The institution fosters a multidisciplinary approach, collaborating with various experts to conduct high-quality clinical trials aimed at improving health outcomes across a wide range of medical fields. With a strong emphasis on ethical standards and patient welfare, IRCCS Azienda Ospedaliero-Universitaria di Bologna plays a vital role in shaping the future of medicine through rigorous scientific inquiry and patient-centered care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bologna, , Italy
Patients applied
Trial Officials
Eugenio Brunocilla, Prof, MD
Principal Investigator
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported